Search research articles
Contact Us
Filters
Showing results (21-30 of 381) with videos related to
Page
of 39
Sort By:
Journal of Clinical Psychopharmacology
|
May 16, 2007
The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 or CYP2C19
Jose de Leon
The American Journal of Psychiatry
|
May 3, 2014
DSM-5 and the research domain criteria: 100 years after Jaspers' General psychopathology
Jose de Leon
Journal of Clinical Psychopharmacology
|
April 11, 2014
False-negative studies may systematically contaminate the literature on the effects of inducers in neuropsychopharmacology: part II: focus on bipolar disorder
Jose de Leon
Acta Neuropsychiatrica
|
December 3, 2014
Focusing on drug versus disease mechanisms and on clinical subgrouping to advance personalised medicine in psychiatry
Jose de Leon
British Journal of Clinical Pharmacology
|
September 15, 2022
According to the WHO clozapine pharmacovigilance database, the United Kingdom accounts for 968 fatal outcomes versus 892 in the rest of the world
Jose de Leon
Revista De Psiquiatria Y Salud Mental
|
March 10, 2015
The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part I: A summary of the current state for clinicians
Jose de Leon
The American Journal of Psychiatry
|
June 2, 2014
Response to Gorelick
Jose de Leon
Acta Neuropsychiatrica
|
April 8, 2015
Is psychiatry only neurology? Or only abnormal psychology? Déjà vu after 100 years
Jose de Leon
Pharmacogenomics
|
August 4, 2021
Tools for optimizing pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants
Jose de Leon
The International Journal of Neuropsychopharmacology
|
August 6, 2003
Glucuronidation enzymes, genes and psychiatry
Jose de Leon
Page
of 39
Search research articles
Search
Showing results (21-30 of 381) with videos related to
Sort By:
Page
of 39
Journal of Clinical Psychopharmacology
|
May 16, 2007
The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 or CYP2C19
Jose de Leon
The American Journal of Psychiatry
|
May 3, 2014
DSM-5 and the research domain criteria: 100 years after Jaspers' General psychopathology
Jose de Leon
Journal of Clinical Psychopharmacology
|
April 11, 2014
False-negative studies may systematically contaminate the literature on the effects of inducers in neuropsychopharmacology: part II: focus on bipolar disorder
Jose de Leon
Acta Neuropsychiatrica
|
December 3, 2014
Focusing on drug versus disease mechanisms and on clinical subgrouping to advance personalised medicine in psychiatry
Jose de Leon
British Journal of Clinical Pharmacology
|
September 15, 2022
According to the WHO clozapine pharmacovigilance database, the United Kingdom accounts for 968 fatal outcomes versus 892 in the rest of the world
Jose de Leon
Revista De Psiquiatria Y Salud Mental
|
March 10, 2015
The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part I: A summary of the current state for clinicians
Jose de Leon
The American Journal of Psychiatry
|
June 2, 2014
Response to Gorelick
Jose de Leon
Acta Neuropsychiatrica
|
April 8, 2015
Is psychiatry only neurology? Or only abnormal psychology? Déjà vu after 100 years
Jose de Leon
Pharmacogenomics
|
August 4, 2021
Tools for optimizing pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants
Jose de Leon
The International Journal of Neuropsychopharmacology
|
August 6, 2003
Glucuronidation enzymes, genes and psychiatry
Jose de Leon
Page
of 39